Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.
José Carlos Bouso, Eduardo José Pedrero-Pérez, Sam Gandy, Miguel Ángel Alcázar‐córcoles
Human Psychopharmacology: Clinical and Experimental September 1, 2016 DOI: 10.1002/hup.2545 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Psychometric study Peer reviewed |
|---|---|
| Sample size | 158 |
| Population | 158 subjects (100 men) after taking ayahuasca |
| Intervention | Ayahuasca |
| Topics | Ayahuasca |
| Keywords | Psychedelics Psychometrics |
| Citations | 48 |
| Key points | The factor structures of the HRS, MEQ, and ARCI only sparsely matched their theoretical proposals when administered to 158 ayahuasca users. |
Abstract
In the present study we explored the psychometric properties of three widely used questionnaires to assess the subjective effects of hallucinogens: the Hallucinogen Rating Scale (HRS), the Mystical Experience Questionnaire (MEQ), and the Addiction Research Center Inventory (ARCI). These three questionnaires were administered to a sample of 158 subjects (100 men) after taking ayahuasca, a hallucinogen whose main active component is N,N-dimethyltryptamine (DMT). A confirmatory factorial study was conducted to check the adjustment of previous data obtained via theoretical proposals. When this was not possible, we used an exploratory factor analysis without restrictions, based on tetrachoric and polychoric matrices and correlations. Our results sparsely match the theoretical proposals of the authors, perhaps because previous studies have not always employed psychometric methods appropriate to the data obtained. However, these data should be considered preliminary, pending larger samples to confirm or reject the proposed structures obtained. It is crucial that instruments of sufficiently precise measurement are utilized to make sense of the information obtained in the study of the subjective effects of psychedelic drugs. Copyright © 2016 John Wiley & Sons, Ltd.
Citations in the library
Cited by 38
- Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Current Topics in Behavioral Neurosciences 2018
- Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews Expert Review of Clinical Pharmacology August 13, 2018
- Unifying Theories of Psychedelic Drug Effects Frontiers in Pharmacology March 2, 2018
- Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD Journal of Psychopharmacology January 9, 2021
- Subanaesthetic ketamine and altered states of consciousness in humans British Journal of Anaesthesia April 13, 2018
and 33 more in the library
Cites 57
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Proceedings of the National Academy of Sciences January 23, 2012
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
and 52 more in the library